Source comparison
Best Hexarelin Dosage Growth Hormone Release 2026: Protocol Comparison
Low-Dose Sustained 100 mcg 2×/day Twice daily (morning, pre-bed) 4 weeks on, 2 weeks off 18–24 ng/mL Moderate. Desensitization still occurs but slower Best for first-time users prioritizing safety and sustained mild elevation Standard Protocol 150 mcg 2×/day T
This comparison does not assign a generated winner or score.
- Low-Dose Sustained
- 100 mcg 2×/day
- Twice daily (morning, pre-bed)
- 4 weeks on, 2 weeks off
- 18–24 ng/mL
- Moderate. Desensitization still occurs but slower
- Best for first-time users prioritizing safety and sustained mild elevation
- Standard Protocol
- 150 mcg 2×/day
- Twice daily (morning, afternoon)
- 24–30 ng/mL
- Moderate. Manageable with strict cycling
- Optimal balance of GH output and receptor preservation for most research applications
- High-Dose Pulsatile
- 200 mcg 3×/day
- Three times daily (morning, afternoon, pre-bed)
- 28–35 ng/mL
- High. Requires disciplined cycling and monitoring
- Maximum pulsatile GH exposure. Used in advanced protocols where GH output is prioritized
- Continuous Daily (No Cycling)
- 100–200 mcg/day
- Once or twice daily
- No cycling. Continuous use
- 18–24 ng/mL initially, declining to 8–12 ng/mL by week 6
- Severe. Full desensitization within 6–8 weeks
- Not recommended. Receptor downregulation eliminates efficacy and wastes peptide
- Rotating Peptide Stack
- 150 mcg 2×/day (hexarelin) alternating with ipamorelin
- Twice daily
- 4 weeks hexarelin, 4 weeks ipamorelin, repeat
- 20–28 ng/mL sustained
- Low. Cross-desensitization minimized
- Effective for long-term protocols extending beyond 12 weeks